Skip to main content

Table 4 Multivariable analysis of OS and BCSS in OBC patients

From: Clinicopathological characteristics and treatment outcomes of occult breast cancer: a population-based study

Variables

OS

BCSS

HR

95% CI

P-value

HR

95% CI

P-value

Age (year)

  

 < 40

Reference

     

 40–49

0.57

0.27–1.19

0.13

0.64

0.26–1.56

0.32

 50–59

0.82

0.43–1.58

0.56

0.82

0.36–1.85

0.64

 60–69

1.04

0.55–1.99

0.90

0.97

0.43–2.18

0.93

 ≥ 70

2.15

1.13–4.08

0.02

1.52

0.67–3.41

0.31

Race

  

 White

Reference

  

Reference

  

 Black

0.90

0.56–1.47

0.68

 Asian or Pacific Islander

0.39

0.16–0.97

0.04

 American Indian/Alaska Native

4.25

1.01–17.99

0.05

 Unknown/other

1.23 × 10–6

0-INF

0.99

Marital status

  

 Not married

Reference

  

 Married

0.80

0.62–1.02

0.07

 Unknown

1.25

0.68–2.31

0.48

Grade

  

 I/II

Reference

  

Reference

  

 III

0.90

0.51–1.59

0.71

1.71

0.65–4.47

0.27

 IV

0.66

0.22–2.04

0.47

0.65

0.07–5.73

0.70

 Unknown

0.70

0.41–1.19

0.18

1.26

0.50–3.16

0.63

N

  

 N1mi

Reference

  

Reference

  

 N1

1.34 × 1011

0-INF

0.99

1.17 × 1013

0-INF

1.00

 N2

1.72 × 106

0-INF

0.99

4.04 × 107

0-INF

1.00

 N3

3.44

0.79–14.92

0.10

4.47

0.58–34.38

0.15

No. of positive LN

  

 1–3

Reference

  

Reference

  

 4–9

2.09

1.17–3.73

0.01

1.96

0.95–4.02

0.07

 ≥ 10

1.53

0.86–2.73

0.15

2.28

1.16–4.46

0.02

 Other/Unknown

2.47

1.76–3.47

  <   0.001

3.26

2.07–5.13

  <   0.001

Stage

  

 IB

Reference

  

Reference

  

 IIA

1.39 × 10–11

0-INF

0.99

1.45 × 10–13

0-INF

1.00

 IIIA

9.80 × 10–7

0-INF

0.99

6.46 × 10–8

0-INF

1.00

 IIIC

NA

NA

NA

NA

NA

NA

Radiation

  

 None/Unknown

Reference

  

Reference

  

 Yes

0.68

0.52–0.88

0.003

0.63

0.45–0.88

0.007

Chemotherapy

  

 Yes

Reference

  

Reference

  

 No/Unknown

0.87

0.52–1.44

0.59

1.08

0.51–2.28

0.84

Type of systemic therapy

    

 Neoadjuvant

Reference

  

Reference

  

 Adjuvant

0.93

0.58–1.50

0.77

1.00

0.57–1.75

0.99

 Neoadjuvant + adjuvant

0.50

0.23–1.10

0.08

0.69

0.30–1.59

0.38

 Only systemic therapy, no surgery

1.88

0.90–3.90

0.09

2.40

1.03–5.60

0.04

 Other

0.55

0.32–0.96

0.04

0.46

0.23–0.93

0.03

 No/Unknown

1.02

0.51–2.06

0.95

1.23

0.48–3.17

0.67

Subtypes

      

 Luminal A

Reference

  

Reference

  

 Luminal B

0.63

0.31–1.31

0.22

0.65

0.26–1.60

0.35

 HER2 positive

1.10

0.54–2.22

0.79

1.31

0.56–3.02

0.53

 Triple negative

1.42

0.81–2.50

0.22

1.66

0.81–3.40

0.17

 Unknown

1.53

1.02–2.27

0.04

1.64

0.97–2.76

0.06

ER

      

 Negative

Reference

  

Reference

  

 Borderline/Unknown

1.13

0.51–2.54

0.76

1.63

0.63- 4.18

0.31

 Positive

0.78

0.53–1.14

0.20

0.87

0.52–1.43

0.57

PR

      

 Negative

Reference

  

Reference

  

 Borderline/Unknown

0.85

0.41–1.79

0.68

0.72

0.29–1.74

0.46

 Positive

0.99

0.69–1.43

0.98

0.78

0.49–1.24

0.30

  1. BCSS breast cancer-specific survival, CI confidence interval, ER estrogen receptor, HR hazard ratio, INF infinite, N N staging of OBC, NA not available, OS overall survival, PR progesterone receptor